LOGIN
ID
PW
MemberShip
2024-12-13 01:09
All News
Policy
Company
Product
Opinion
InterView
°Ë»ö
Dailypharm Live Search
Close
Product
Gout drug allopurinol side effect alert
by
Kang, Shin-Kook
Nov 20, 2024 06:08am
As reports of adverse reactions to allopurinol, a drug prescribed for gout, continue to mount, health authorities are calling for genetic testing of patients before prescribing it to prevent side effects. According to medical and pharmaceutical associations on the 19th, the NMC Adverse Drug Reaction&160;Committee recently reviewed applicatio
Product
MOHW cautions non-face-to-face Wegovy prescriptions
by
Kang Hye-Kyung
Nov 13, 2024 05:55am
The government has asked medical institutions for cooperation in making indiscriminate Wegovy prescriptions. The Ministry of Health and Welfare said on the 11th through the medical community, ¡°Regarding Wegovy, which was recently released as a treatment for obesity, medical institutions are issuing prescriptions without sufficiently e
Product
KTIC, ¡¯21s Wegovy prescriptions, not a telemedicine issue'
by
Kang, Hye-Kyung
Nov 7, 2024 05:47am
the platform industry has spoken out to state its opinion regarding the government¡¯s move to restrict non-face-to-face prescriptions in response to the criticism that 'obesity drugs are being easily prescribed &8211; just in 21 seconds - through non-face-to-face medical treatment platforms.¡¯ While the platform industry sympathizes with
Product
KMA ¡®non-face-to-face Wegovy prescriptions cause harm'
by
Kang, Shin-Kook
Oct 30, 2024 05:53am
A Korean doctor's association has called for an immediate halt to the government's plan to allow non-face-to-face medical treatment. The Korean Medical Association (Chairman Hyun-Taek Lim) issued a statement on the 28th claiming, ¡°The government should immediately stop allowing all non-face-to-face medical treatment as its pilot project
Product
AZ seeks to reaffirm Tagrisso¡¯s position in NSCLC
by
Moon, sung-ho
Oct 25, 2024 05:49am
Se-hoon Lee, a Professor at Samsung Medical Center, recently gained attention by publishing a study on Leclaza (lazertinib, Yuhan Corp), a domestic third-generation EGFR TKI (Tyrosine Kinase Inhibitor). With the advent of another option to the global standard therapy option Tagrisso (osimertinib) increasing the number of treatment options to
Product
Stockpiled COVID-19 drugs soon to expire in KOR
by
Kim JiEun
Oct 23, 2024 05:49am
A corona drug that caused a crisis due to its shortage has become a nuisance, an inventory glut, in just 3-4 months. In August, the government additionally distributed large quantities of the treatments, but the number of confirmed COVID-19 cases plummeted. The expiry date of the supply is approaching, raising the possibility of mass d
Product
Illegal errand companies deliver Wegovy for ₩10,000
by
Jung, Heung-Jun
Oct 22, 2024 05:52am
Amid the craze for obesity treatment drug Wegovy, errand companies are also thriving by offering pharmacy proxy pick-up and delivery services. These are illegal businesses that take advantage of the fact that consumers are looking for a low-priced source of the non-reimbursed drug, as the price varies greatly depending on the pharmacy.
Product
Consumers use tricks to receive Wegovy prescriptions
by
Kang, Hye-Kyung
Oct 22, 2024 05:51am
With heating interest in the obesity drug Wegovy, the way-around measures the consumers are taking to receive prescriptions are causing controversy. From how to receive Wegovy through non-face-to-face treatment venues without the legwork to how to split the high-dose formulations being shared online, concerns are growing over the drug¡¯s
Product
Wegovy's price varies by pharmacy in Korea
by
Jung, Heung-Jun
Oct 17, 2024 05:51am
The price of Wegovy, which has been attracting much attention since its launch in Korea, has been found to vary greatly, ranging from KRW 420,000 to KRW 800,000. Some pharmacists who have not yet decided on the selling price are referring to the prices of in-house prescriptions at hospitals and local pharmacies. The prices of Wegovy at p
Product
¡®Disclose the pricing rationale used for COVID-19 drugs'
by
Kang, Hye-Kyung
Oct 2, 2024 05:49am
The Korean Pharmacists for Democratic Society (CEO Kyungrim Jeon, KPDS) has called for the disclosure of the cost-effectiveness evaluation results of the COVID-19 treatments Paxlovid and Veklury Inj. ¡°The Ministry of Health and Welfare is engaging in the atrocity of setting excessive drug prices for COVID-19 treatments,¡± said the KPDS o
1
2
3
4
5
6
7
8
9
10
>